Related Experiment Videos
[Clinical studies of cefoperazone in pediatric field (author's transl)]
Insights
Cefoperazone (CPZ) showed 80% efficacy in treating pediatric infections, including a 100% success rate for urinary tract infections. This antibiotic was well-tolerated, with only one mild adverse event reported in children.
Area of Science:
- Pediatric Infectious Diseases
- Antibiotic Therapy
- Pharmacokinetics and Pharmacodynamics
Context:
- Childhood infections pose a significant health burden globally.
- Intravenous antibiotics are crucial for severe pediatric infections.
- Cefoperazone is a third-generation cephalosporin with broad-spectrum activity.
Purpose:
- To evaluate the clinical efficacy and safety of cefoperazone in pediatric patients.
- To determine the effectiveness of cefoperazone in treating various infections, including urinary tract, respiratory, and gastrointestinal infections.
- To assess the tolerability and adverse effects of cefoperazone in children.
Summary:
- Clinical studies administered intravenous cefoperazone (CPZ) at 107 mg/kg/day to 10 children with infections (UTI, respiratory, enterocolitis).
- An overall efficacy rate of 80% was observed, with a 100% efficacy in treating urinary tract infections, including one caused by Pseudomonas aeruginosa.
- One case of bloody stools was noted, resolving gradually, with no significant abnormal laboratory findings, indicating good tolerability.
Impact:
- Cefoperazone demonstrates significant efficacy in treating pediatric infections, particularly urinary tract infections.
- The favorable safety profile suggests cefoperazone as a viable treatment option for pediatric patients.
- Further research could explore optimal dosing and long-term outcomes in pediatric populations.
Abstract:
Clinical studies of cefoperazone (CPZ) were performed and the following results were obtained. 1) CPZ was intravenously administered at the daily dose of 35 approximately 107 mg/kg to 10 children with infection: urinary tract infection (6 cases), respiratory infection (3 cases), and acute enterocolitis (1 case). The overall efficacy rate was 80%, and in urinary tract infection including one case caused by Pseudomonas aeruginosa, efficacy rate was 100%. 2) The bloody stools were noted in one case, 2 days after the administration of CPZ, but improved gradually. No abnormal laboratory data were found.